Qyuns Therapeutics Co., Ltd. (QYUNS-B) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 9 April 2026, covering the month ended 31 March 2026.

The company’s authorised and registered share capital remained unchanged at 227.07 million ordinary H shares, each with a par value of RMB 1, translating into total authorised capital of RMB 227.07 million.

Issued share metrics were also stable: • Issued shares (excluding treasury): 224.57 million • Treasury shares: 2.50 million • Total issued shares: 227.07 million No new shares were issued, cancelled, or repurchased during the reporting month.

QYUNS-B affirmed that it satisfied the Main Board’s minimum public float requirement of 25 percent as of 31 March 2026.

The filing states there were no outstanding share options, warrants, convertible securities, or other agreements that could lead to further share issuance, and no movements in Hong Kong Depositary Receipts.

All requisite confirmations under Main Board Rule 13.25C were provided by Board Secretary and Joint Company Secretary Hu Yanbao, indicating full compliance with listing and regulatory obligations.